Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC

Share this content:
Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC
Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC

THURSDAY, Oct. 18, 2018 (HealthDay News) -- Integration of plasma next-generation sequencing (NGS) into the routine management of metastatic non-small cell lung cancer (NSCLC) results in an increase in the detection of therapeutically targetable mutations, according to a study published online Oct. 11 in JAMA Oncology.

Charu Aggarwal, M.D., M.P.H., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted a prospective cohort study involving 323 patients with metastatic NSCLC who had plasma testing ordered. A 73-gene commercial platform was used to perform plasma NGS.

The researchers found that therapeutically targetable mutations were detected in 35 percent of patients in EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF. Overall, 29.1 percent of patients had plasma testing only at the discretion of the treating physician or patient preference; 33 percent of these 94 patients had a therapeutically targetable mutation, averting the need for invasive biopsy. Among the remaining 229 patients who had concurrent plasma and tissue NGS or who were unable to have tissue NGS, a therapeutically targetable mutation was detected in tissue alone in 20.5 percent; the addition of plasma testing increased this percentage to 35.8 percent. Most (85.7 percent) of the 42 patients with a targeted therapy based on the plasma result achieved a complete or partial response or stable disease.

"Given the ease of obtaining plasma-based genotyping and the success observed with such a non-invasive approach, our results argue for incorporation of plasma-based genotyping into routine clinical management of patients with NSCLC," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »